Costs of biomarker testing in advanced non‐small cell lung cancer: a global study comparing next‐generation sequencing and single‐gene testing

Costs of biomarker testing in advanced non‐small cell lung cancer: a global study comparing next‐generation sequencing and single‐gene testing

Abstract Current European/US guidelines recommend that molecular testing in advanced non‐small cell lung cancer (aNSCLC) be performed using next‐generation sequencing (NGS). However, the global uptake of NGS is limited, largely owing to reimbursement constraints. We compared real‐world costs of NGS...

Full description

Saved in:
Bibliographic Details
Main Authors: Umberto Malapelle, Chien‐Chin Chen, Enrique deÁlava, Paul Hofman, Daniel Kazdal, Tae‐Jung Kim, Tony Kiat Hon Lim, Aleš Ryška, Angelica A Saetta, Ed Schuuring, Giancarlo Troncone, Michele Biscuola, Yi‐Lin Chen, Gek San Tan, Charles Hugo Marquette, Maria Michelli, Arja terElst, Hana Vošmiková, Joshua Kapp, Sebastian Gonzalez‐McQuire, Andromachi Giannopoulou, Jean Marie Franzini, Victoria Lucia Rabsiun Aramburu, Anna Baggi, Albrecht Stenzinger
Format: Article
Language:English
Published: Wiley 2025-03-01
Series:The Journal of Pathology: Clinical Research
Subjects:
cost comparison
next‐generation sequencing
NSCLC
precision medicine
predictive biomarker
single‐gene testing
Online Access:https://doi.org/10.1002/2056-4538.70018
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/2056-4538.70018

Similar Items